Genetic polymorphism at BCL2 as a predictor for rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone efficacy in patients with diffuse large B-cell lymphoma

Morteza Bashash,Joseph M. Connors,Randy D. Gascoyne,Barbara Meissner,Johanna M. Schuetz,Stephen Leach,Graham W. Slack,Brian Berry,Howard Hu,Laurie H. Sehn,Angela Brooks-Wilson,John J. Spinelli

HAEMATOLOGICA（2017）

引用 5|浏览28

暂无评分

摘要

In the study herein, we examine the usefulness of germline BCL2 single-nucleotide polymorphisms (SNP) in identifying low- and high-risk patients. Our initial study identified 2 constitutional BCL2 SNPs significantly associated with survival of DLBCL patients treated with R-CHOP. We independently

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要